As of 2025-07-11, the Intrinsic Value of Hangzhou Tigermed Consulting Co Ltd (300347.SZ) is 28.93 CNY. This 300347.SZ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 57.88 CNY, the upside of Hangzhou Tigermed Consulting Co Ltd is -50.00%.
The range of the Intrinsic Value is 18.26 - 73.37 CNY
Based on its market price of 57.88 CNY and our intrinsic valuation, Hangzhou Tigermed Consulting Co Ltd (300347.SZ) is overvalued by 50.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 18.26 - 73.37 | 28.93 | -50.0% |
| DCF (Growth 10y) | 25.93 - 103.84 | 41.13 | -28.9% |
| DCF (EBITDA 5y) | 31.04 - 55.75 | 40.06 | -30.8% |
| DCF (EBITDA 10y) | 36.78 - 74.86 | 50.41 | -12.9% |
| Fair Value | 4.88 - 4.88 | 4.88 | -91.57% |
| P/E | 6.88 - 15.46 | 10.28 | -82.2% |
| EV/EBITDA | 12.92 - 20.74 | 16.55 | -71.4% |
| EPV | 10.24 - 18.00 | 14.12 | -75.6% |
| DDM - Stable | 2.81 - 14.73 | 8.77 | -84.9% |
| DDM - Multi | 17.63 - 59.65 | 26.02 | -55.0% |
| Market Cap (mil) | 50,063.30 |
| Beta | 1.62 |
| Outstanding shares (mil) | 864.95 |
| Enterprise Value (mil) | 50,885.03 |
| Market risk premium | 6.13% |
| Cost of Equity | 10.02% |
| Cost of Debt | 5.00% |
| WACC | 9.70% |